반려동물 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of companion animal vaccines Market

The global companion animal vaccines market is witnessing significant growth, driven by rising pet ownership, advancements in veterinary healthcare, and increasing awareness of animal health. The market was valued at USD 5.67 billion in 2025, projected to grow to USD 5.94 billion in 2026, and expected to reach USD 10.35 billion by 2034, reflecting a CAGR of 7.19% during the forecast period. North America dominated the market in 2025 with a 43.55% share, attributed to advanced veterinary infrastructure, well-established immunization programs, and the presence of major players such as Zoetis Services LLC, Elanco, and Virbac.

Companion animal vaccines play a critical role in protecting pets from infectious diseases, improving their quality of life, and reducing the need for costly treatments. They are essential in controlling epizootic outbreaks and ensuring overall animal health.

Market Drivers

The growth of the companion animal vaccines market is primarily driven by:

• Increasing pet ownership: The rising adoption of dogs, cats, and other companion animals globally drives vaccine demand. For example, in Canada, the dog population increased from 7.6 million to 7.7 million between 2019 and 2021.
• Strategic collaborations and product launches: Companies such as Elanco and Zoetis are actively launching new vaccines and partnering on research initiatives.
• Growing awareness of zoonotic diseases: Pet owners increasingly recognize the importance of preventive healthcare.
• Emerging veterinary healthcare infrastructure and pet insurance: Expansion of pet insurance programs encourages routine vaccinations and preventive care.

Market Restraints

Certain factors limit the market growth:

• Limited access to veterinary services in developing countries: Geographic, economic, and infrastructural challenges reduce vaccine penetration. Only about 40% of veterinary practitioners follow current vaccination guidelines in some regions.
• High development costs: Vaccine research, clinical trials, and regulatory approvals require significant investment.
• Regulatory hurdles: Stringent safety and efficacy standards extend product approval timelines.
• Logistical challenges: Maintaining cold chains for vaccine distribution adds complexity and cost, particularly in rural and underdeveloped areas.

Market Opportunities

• Rising adoption of pet insurance: As pets are increasingly considered family members, pet insurance programs covering routine vaccinations create a stable growth platform. For instance, Future Generali India sold nearly 25,000 pet insurance policies in Q4 2022, highlighting the expanding market potential.
• Technological advancements: Innovations such as recombinant and DNA vaccines enable broader and more effective immunization programs.

Market Trends

• Focus on preventive healthcare: Pet owners are increasingly seeking vaccinations to prevent diseases rather than treat them.
• Innovative vaccine launches: For example, in November 2024, Boehringer Ingelheim launched EURICAN L4 for leptospirosis in dogs.
• Combination vaccines: Multivalent vaccines offering protection against multiple diseases improve compliance and convenience.

Segmentation Analysis

By Product Type

• Live attenuated vaccines dominate due to long-lasting immune response and frequent product launches.
• Inactivated vaccines hold the second-largest share.
• Recombinant vaccines are expected to grow at the highest CAGR due to enhanced efficacy and ability to target multiple pathogens.

By Animal Type

• Canine vaccines lead the market due to high adoption rates and preventive healthcare awareness.
• Feline vaccines are growing rapidly with increased cat adoption and launches like NOBIVAC NXT FeLV in September 2024.
• Other animals such as rabbits and ferrets are also contributing to niche market growth.

By Route of Administration

• Parenteral vaccines dominate due to proven efficacy and strong immune responses.
• Oral vaccines are growing due to ease of administration and mucosal immunity targeting, particularly for stray animals.
• Other routes (intranasal, transdermal) are emerging as convenient alternatives.

By Distribution Channel

• Veterinary clinics hold the largest market share, supported by rising numbers of clinics and professional veterinary care.
• Veterinary hospitals and pharmacies/drug stores are also growing steadily.

Regional Insights

• North America: Market size USD 2.48 billion in 2025, led by the U.S., with advanced veterinary facilities and immunization programs.
• Europe: Second-largest market, driven by high pet populations in the U.K., Germany, and France, along with government initiatives.
• Asia Pacific: Fastest-growing region due to rising disposable incomes, increasing pet adoption, and expanding veterinary infrastructure.
• Latin America & Middle East & Africa: Moderate growth expected, supported by increasing demand for effective vaccines and improved veterinary care.

Key Industry Players

Major companies include Zoetis Services LLC, Elanco, Merck Animal Health, Boehringer Ingelheim, Virbac, HIPRA, Ceva, NEOGEN, and Hester Biosciences. Their growth strategies involve robust R&D, innovative product launches, global expansions, and strategic collaborations. Notable developments include:

• June 2024: Merck Animal Health launched NOBIVAC NXT Rabies portfolio in Canada.
• February 2024: Mumbai Rabies Elimination Project launched a stray dog vaccination drive.
• September 2022: Merck Animal Health acquired Vence to advance animal health technologies.

Conclusion

The global companion animal vaccines market is projected to grow from USD 5.67 billion in 2025 to USD 10.35 billion by 2034, at a CAGR of 7.19%. Market expansion is driven by rising pet adoption, preventive healthcare awareness, technological innovations, and increasing pet insurance coverage. North America dominates, while Asia Pacific shows the fastest growth. The market is expected to benefit from new product launches, improved veterinary infrastructure, and strategic initiatives by leading industry players, ensuring better animal health and broader immunization coverage worldwide.

Segmentation By Product

• Inactivated
• Live Attenuated
• Recombinant
• Others

By Animal Type

• Feline
• Canine
• Avian
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region

• North America (By Product, Animal Type, Route of Administration, Distribution Channel, Country/ Sub-Region)
  • U.S.
  • Canada
• Europe (By Product, Animal Type, Route of Administration, Distribution Channel, Country/ Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Animal Type, Route of Administration, Distribution Channel, Country/ Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Animal Type, Route of Administration, Distribution Channel, Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Animal Type, Route of Administration, Distribution Channel, Country/ Sub-Region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Animal Diseases by Key Countries, By Key Countries/ Region, 2025
• 4.2. Regulatory Scenario By Key Countries/ Region, 2025
• 4.3. Pet Ownership Statistics, By Key Countries/ Region, 2025
• 4.4. Overview of Vaccination for Different Animal Diseases
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.7. Impact of COVID-19 on the Global Companion Animal Vaccines Market

5. Global Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Animal Type
  • 5.2.1. Feline
  • 5.2.2. Canine
  • 5.2.3. Avian
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Veterinary Hospitals
  • 5.4.2. Veterinary Animal Clinics
  • 5.4.3. Pharmacies & Drug Stores
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Animal Type
  • 6.2.1. Feline
  • 6.2.2. Canine
  • 6.2.3. Avian
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Veterinary Hospitals
  • 6.4.2. Veterinary Animal Clinics
  • 6.4.3. Pharmacies & Drug Stores
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Animal Type
  • 7.2.1. Feline
  • 7.2.2. Canine
  • 7.2.3. Avian
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Veterinary Hospitals
  • 7.4.2. Veterinary Animal Clinics
  • 7.4.3. Pharmacies & Drug Stores
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Animal Type
  • 8.2.1. Feline
  • 8.2.2. Canine
  • 8.2.3. Avian
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Veterinary Hospitals
  • 8.4.2. Veterinary Animal Clinics
  • 8.4.3. Pharmacies & Drug Stores
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Animal Type
  • 9.2.1. Feline
  • 9.2.2. Canine
  • 9.2.3. Avian
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Veterinary Hospitals
  • 9.4.2. Veterinary Animal Clinics
  • 9.4.3. Pharmacies & Drug Stores
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Companion Animal Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Animal Type
  • 10.2.1. Feline
  • 10.2.2. Canine
  • 10.2.3. Avian
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Veterinary Animal Clinics
  • 10.4.3. Pharmacies & Drug Stores
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Elanco
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. HIPRA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Virbac
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Merck Animal Health
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Zoetis Services LLC
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Ceva
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. NEOGEN CORPORATION
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Hester Biosciences Limited
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)